Aim: The aim of the study was an evaluation of validity measures of the CASS (Clinical Assessment of Schizophrenic Syndromes)--a new multi-purpose and multi-level clinical diagnostic instrument consisting of a diagnostic questionnaire (CASS-D) allowing to analyze a diagnosis of schizophrenia according to DSM-IV and ICD-10 criteria as well as of three rating scales designed for description and intensity evaluation of schizophrenic syndromes on the global (CASS-G), dimensional (CASS-P, a profile of 13 basic dimensions) or symptomatological (CASS-S, a set of 31 symptoms) level.

Subjects: 194 inpatients consecutively admitted to the Department within approximately 6 months were assessed twice (at the start and end of their hospitalization) by 12 trained diagnosticians.

Method: Several measures of validity were analyzed. Results obtained by means of CASS were compared with results of the SANS/SAPS, BPRS, and PANSS as reference rating scales (diagnostic validity). Characteristics of frequency, intensity, dynamics and specificity of scale items were used to analyze content validity. Factorial structure of CASS scales was applied as a measure of construct validity.

Findings: Diagnostic validity of the new instrument seems to be confirmed by its very high correlation coefficients with rating scales recognized as international standards: BPRS, PANSS, and SANS/SAPS. Reasonable characteristics of frequency, intensity, dynamics and specificity of individual items (dimensions, symptoms) and sum scores of CASS scales and relationships between their values strongly suggest their content validity. Both sum (CASS-P, CASS-S) and global (CASS-G) scores of scales under study revealed some specificity--they had significantly higher values in patients with schizophrenia than in patients with other diagnoses. It allows to distinguish in a schizophrenic syndrome described by CASS components which are specific and not specific for this disorder. The latter have been left also in the final version for their practical and clinical importance. Construct validity of the CASS was studied separately for different scales (CASS-P, CASS-S) and different groups (all or only schizophrenic patients) by means of several factor analyses, and performed along identical statistical procedure (principal component method of extraction with criterion eigenvalue > 1, followed by Equamax rotation). Resulting solutions could be interpreted reasonably and consistently with contemporary attempts to find adequate factorial models of intrinsic structure of schizophrenic syndrome. Thus they support confidence for constructive aspect of the CASS validity.

Conclusions: Ultimately, results obtained in the study suggest that the CASS may be considered as an instrument with some promising indices of diagnostic, content and construct validity, which may be potentially useful for clinical and research purposes.

Download full-text PDF

Source

Publication Analysis

Top Keywords

schizophrenic syndrome
12
rating scales
12
cass
9
validity
9
assessment schizophrenic
8
global cass-g
8
bprs panss
8
diagnostic validity
8
characteristics frequency
8
frequency intensity
8

Similar Publications

Dissociative psychosis or dissociative schizophrenia? Comparison of two phenomena.

BMC Psychiatry

January 2025

Department of Psychiatry, University of Health Sciences, Erzurum City Hospital, Erzurum, 25100, Turkey.

Background: In recent years, researchers have reported crucial advances in the understanding of "Dissociative psychosis" and "Dissociative schizophrenia". While clinical studies in this area have been sustained for well, it remains to be established for some aspects that a clear and valid relationship exists between dissociation, childhood traumatic experiences, and schizophrenia or psychotic spectrum disorders.

Methods: To test such hypotheses, we divided the patients into two groups; the first group consisted of patients with psychotic disorders not otherwise specified (PNOS), and the second group consisted of schizophrenic patients.

View Article and Find Full Text PDF

Objective: Therapeutic drug monitoring (TDM) indicators have been suggested to predict overall outcome responses to olanzapine (OLZ) treatments in terms of efficacy and metabolic syndrome. This study aimed to investigate whether paraoxonase-1 (PON-1) activity can be used to predict schizophrenia patient outcomes.

Methods: Schizophrenic patients ( = 50) aged between 20 and 65 years who received OLZ treatment were recruited, and their Positive and Negative Syndrome Scale scores, PON-1 activity, and olanzapine drug levels normalized by dose (OLZ/D) and its metabolite N-desmethyl-olanzapine (DMO), together with biochemical parameters, were determined.

View Article and Find Full Text PDF

Background: Negative symptoms of schizophrenia represent an unmet therapeutic need for many patients in whom pentoxifylline may be effective in terms of its dopaminergic, anti-inflammatory, and cerebral blood flow-increasing properties. This study aimed to evaluate pentoxifylline as a therapeutic agent for improving negative symptoms of schizophrenia.

Methods: Chronic schizophrenia outpatients experiencing significant negative symptoms were randomly allocated to receive pentoxifylline 400 mg or matched placebo every 12 hours for 8 weeks.

View Article and Find Full Text PDF

Disentangling the topological symptom structure of schizophrenia: A network analysis.

Schizophr Res

January 2025

Department of Psychiatry, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; Henan International Joint Laboratory of Biological Psychiatry, Zhengzhou University, Zhengzhou, China; Henan Psychiatric Transformation Research Key Laboratory, Zhengzhou University, Zhengzhou, China. Electronic address:

Background And Hypothesis: The Positive and Negative Syndrome Scale (PANSS), comprehensively assesses schizophrenia severity. While network analyses of schizophrenic symptoms have yielded inconsistent results, components of disorganized thought consistently rank high in centrality. The present study aims to explore the centrality of disorganized thought across patient subgroups and its potential as a treatment target.

View Article and Find Full Text PDF

Sex difference in alexithymia and cognitive impairment in chronic schizophrenia: a large sample study based on Chinese Han population.

Eur Arch Psychiatry Clin Neurosci

December 2024

CAS Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, 16 Lincui Road, Hai-Dian District, Beijing, 100101, China.

Sex differences in schizophrenia have been noted across domains such as alexithymia and cognitive function; however, how they interact remains unclear. This study aimed to explore sex differences in the relationship between alexithymia and cognitive function in patients with chronic schizophrenia. A total of 695 patients (464 males and 231 females) who met the DSM-IV diagnostic criteria for schizophrenia were recruited in this cross-sectional study.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!